RAPT Therapeutics

RAPT

Market cap $887M

RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable phase 2 data in chronic spontaneous urticaria, with potential for less frequent dosing than competitors. RAPT's strong cash position, bolstered by a $250 million offering, provides operational runway, but future cash burn for pivotal trials remains a risk.

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $250 million public offering to strengthen balance sheet SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the third quarter and nine months ended September 30, 2025.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in November: Guggenheim's 2nd Annual Healthcare Innovation Conference – Fireside chat on Tuesday, November 11, 2025 at 3:30 p.m.

Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE-mediated food allergy.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share. In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by RAPT. The gross proceeds from the offering to RAPT are expected to be approximately $250.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, RAPT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock RAPT is offering, at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by RAPT. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

RAPT Therapeutics, Inc. (NASDAQ:RAPT ) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Company Participants Sylvia Wheeler Brian Wong - CEO, President & Director William Ho - Chief Medical Officer Conference Call Participants Ana Maria Giménez-Arnau Samuel Slutsky - LifeSci Capital, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Kaveri Pohlman - Clear Street LLC Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Operator Good morning, and welcome to RAPT's conference call. [Operator Instructions] And as a reminder, today's call is being recorded.

Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partnerships, investors are rewarding progress across oncology, immunology, and drug delivery platforms.

Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week study.

-  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing-  Efficacy sustained at Week 16 after a single dose of RPT904-  Well tolerated with no serious adverse events related to study drug-  Jeyou to advance RPT904 to Phase 3 development in China-  RAPT to discuss Phase 3 development path with FDA-  RAPT to host conference call at 8:30 am ET today SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, and Shanghai Jeyou Pharmaceutical Co., Ltd.